Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To examine the efficacy and overall tolerability of the simultaneous initiation of treatment (coinitiation) with triiodothyronine (T3) and a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder (MDD). Sources of date were Medline/Pubmed, EMBASE, the Cochrane database, and program syllabi from major psychiatric meetings held since 1995. The study selection comprised double-blind, randomized clinical trials comparing T3-SSRI coinitiation therapy versus SSRI monotherapy for MDD. Data were extracted with the use of a precoded form. Data from four clinical trials involving a total of 444 patients with MDD were identified and combined using a random effects model. There was no statistically significant difference in terms of remission rates or response rates at week 1, week 2, or at endpoint between the two treatment groups (SSRI+T3 coinitiation therapy vs. SSRI monotherapy). Pooled response and remission rates at endpoint for the SSRI+T3 versus SSRI monotherapy groups were 64.6 versus 58.5% and 46.8 versus 44.8%, respectively. In addition, there was no statistically significant difference in overall rates of premature discontinuation of treatment, or in the rate of premature discontinuation of treatment owing to inefficacy or intolerance between the two treatment groups. Notwithstanding important methodological differences between the studies included in the meta-analysis in terms of patient characteristics and treatment protocols, these results do not support the notion that simultaneous initiation of treatment of MDD with an SSRI and T3 is more effective than SSRI monotherapy. However, given the etiologically diverse and clinically heterogeneous nature of MDD, it is at least plausible that T3-SSRIs coinitiation therapy may be effective for a particular subgroup of patients including patients with atypical depression or patients with a functional polymorphism of the D-1 deiodinase gene. Clearly, further work is needed to help determine whether there are specific MDD populations that can, indeed, benefit from T3-SSRI coinitiation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 2×
“…is becoming increasingly clear that contemporary antidepressants, when used as monotherapy for MDD, demonstrate, at best, modest overall efficacy (Fava et al., 2006; McGrath et al., 2006; Rush et al., 2006; Trivedi et al., 2006) as well as a relatively slow onset of action (Quitkin et al., 2003).”
BackgroundAltshuler, L. L., Bauer, M., Frye, M. A., Gitlin, M. J., Mintz, J., Szuba, M. P., Leight, K. L., & Whybrow, P. C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1617 · Cited by 250 · cited 4×
“…of earlier meta-analyses had confirmed that coinitiation therapy was effective in accelerating the antidepressant effects of the TCAs in MDD (Altshuler et al., 2001) or in achieving greater resolution in depressive symptoms at endpoint among patients with TCA-resistant MDD (Aronson et al.,…”
BackgroundResultInfluentialUnderstanding research synthesis (meta-analysis).
Mosteller, F., & Colditz, G. A. (1996) · Annual Review of Public Health · doi:10.1146/annurev.pu.17.050196.000245 · Cited by 228
Cited by
The Link between Thyroid Function and Depression
Hage, M. P., & Azar, S. T. (2012) · Journal of Thyroid Research · doi:10.1155/2012/590648 · Cited by 549
Sex differences and the neurobiology of affective disorders
Rubinow, D. R., & Schmidt, P. J. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0148-z · Cited by 280
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Culpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77
Metadata
- Authors
- Papakostas, G. I., Cooper-Kazaz, R., Appelhof, B. C., Posternak, M. A., Johnson, D. P., Klibanski, A., Lerer, B., & Fava, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2009-01
- Volume
- 24
- Issue
- 1
- Pages
- 19-25
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2164937982
- Cited by
- 45
- References
- 3
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. https://app.cochat.ai/papers/10.1097/yic.0b013e328314dfaf
- The paper
- Papakostas, G. I., Cooper-Kazaz, R., Appelhof, B. C., Posternak, M. A., Johnson, D. P., Klibanski, A., Lerer, B., & Fava, M. (2009). Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e328314dfaf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.